Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02793583 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
A Phase 2 study, sponsored by TG Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 710
- Enrollment target
NCT02793583 is a Phase 2 study that was terminated before completion, run by TG Therapeutics. The registered enrollment target is 710 participants.
The verdict
NCT02793583, a Phase 2 study, was terminated before completion, sponsored by TG Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 710 participants
- Enrollment target
Study Summary
Unity NHL - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
Interventions
- BIOLOGICAL Ublituximab
- DRUG Umbralisib
- BIOLOGICAL Bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2016-05-25 |
| Est. Completion | 2022-07-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02793583
The ClinicalTrials.gov registry entry for NCT02793583 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 710 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ublituximab is the first listed.
NCT02793583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02793583 about?
NCT02793583 is a clinical study titled "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma". Unity NHL - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
What is the current status of trial NCT02793583?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 710 participants. The study started on 2016-05-25. Estimated completion is 2022-07-04.
What interventions are being tested in trial NCT02793583?
The interventions under investigation include: Ublituximab (BIOLOGICAL), Umbralisib (DRUG), Bendamustine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02793583?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.